STOCK TITAN
  1. Home
  2. Sec-filings
  3. EPRX
  4. [6-K] EUPRAXIA PHARMACEUTICALS INC. Current Report (Foreign Issuer)

EP-104GI esophagitis data and DDW investor event for Eupraxia (TSX: EPRX)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Eupraxia Pharmaceuticals Inc. is highlighting new clinical data for its lead candidate EP-104GI in eosinophilic esophagitis at the Digestive Disease Week 2026 conference. The company will present one oral and three poster abstracts from the ongoing Phase 1b/2 RESOLVE trial, including 36‑week histology, endoscopy and symptom durability results.

Eupraxia will also host a virtual investor event on May 4, 2026, featuring key opinion leaders discussing recurrent esophageal strictures and the potential of EP-104GI, a long-acting submucosal corticosteroid injection. The filing also notes earlier success of EP-104IAR, which met its primary endpoint in a Phase 2b knee osteoarthritis trial.

Positive

  • None.

Negative

  • None.
DDW 2026 dates May 2-5, 2026 Digestive Disease Week annual meeting dates in Chicago
Oral presentation time 10:15-10:30 AM CDT EP-104GI oral EoE session on May 3, 2026
Poster session time 12:30-1:30 PM CDT Eosinophilic Esophagitis: Treatment poster session on May 5, 2026
Treatment duration 36 weeks Period over which EP-104GI improvements were observed in RESOLVE
Investor event time 7am CT / 8am ET Virtual investor event at DDW 2026 on May 4
RESOLVE trial phase Phase 1b/2 Ongoing EP-104GI trial in eosinophilic esophagitis
SPRINGBOARD trial phase Phase 2b EP-104IAR knee osteoarthritis pain study meeting primary endpoint
eosinophilic esophagitis medical
"EP-104GI for the treatment of eosinophilic esophagitis (“EoE”)."
A chronic allergic condition in which a type of white blood cell builds up in the tube that carries food from the mouth to the stomach, causing inflammation, difficulty swallowing and chest or throat pain; think of it as sticky residue narrowing a pipe. It matters to investors because prevalence, diagnostic rates and treatment options drive demand for drugs, tests and procedures, and clinical or regulatory news can quickly change revenue and valuation for healthcare companies working on therapies or diagnostics.
Phase 1b/2 medical
"RESOLVE, a Phase 1b/2 dose escalation and optimization trial."
Phase 1b/2 is a combined early-stage human study that first checks a drug’s safety and side effects in a small group and then expands to test whether it shows signs of working in patients. Think of it as a product test that first confirms it’s safe to use, then looks for early evidence of benefit; positive results can significantly reduce clinical risk and increase a company’s value, while negative results raise the opposite.
Diffusphere™ technical
"leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery"
submucosal corticosteroid medical
"EP-104GI is a long-acting submucosal corticosteroid formulation to be injected within esophageal tissues"
esophageal strictures medical
"discuss the definition, prevalence, and treatment of recurrent esophageal strictures."
extended-release products medical
"development of locally delivered, extended-release products that have the potential to address therapeutic areas"
Form 6-K: How Foreign Companies Report to the SEC →
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2026

Commission File Number: 001-41923

EUPRAXIA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)

N/A
(Translation of Registrant’s name)

201-2067 Cadboro Bay Road
Victoria, British Columbia, Canada V8R 5G4
Telephone: (250) 590-3968 
(Address and telephone number of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [   ]      Form 40-F [ X ]

 

 

DOCUMENTS INCLUDED AS PART OF THIS REPORT

Exhibit  
  
99.1 Press Release dated April 22, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  EUPRAXIA PHARMACEUTICALS INC.
   
  
Date: April 22, 2026 By: /s/ Alex Rothwell                     
  Name: Alex Rothwell
  Title: Chief Financial Officer
  

EXHIBIT 99.1

Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting

VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company will present 4 abstracts at Digestive Disease Week (“DDW”) Annual meeting being held May 2-5, 2026 in Chicago, Illinois. Clinical data will be presented from the ongoing Phase 1b/2 RESOLVE trial of EP-104GI for the treatment of eosinophilic esophagitis (“EoE”).

Oral Presentation:

Lecture Session: EoE: Advances in Management
Date: May 3, 2026
Time: 10:15-10:30 AM CDT
Title: Administration of escalating doses of EP-104GI leads to persistent improvements in histological features of eosinophilic esophagitis over 36 weeks in RESOLVE, a Phase 1b/2 dose escalation and optimization trial.
Presenter: Chris Ma, University of Calgary

Poster Presentations:

Poster Session: Eosinophilic Esophagitis: Treatment 
Date: May 5, 2026
Time: 12:30 PM to 1:30 PM CDT

Title: Single administration of EP-104GI in RESOLVE, a Phase 1b/2 trial in eosinophilic esophagitis, improves endoscopic features of inflammation and fibrosis over 36 weeks.
Presenter: Nirmala Gonsalves, Northwestern University

Title: Durability of dysphagia improvements following single administration of EP-104GI in participants with eosinophilic esophagitis during dose escalation in the RESOLVE trial.
Presenter: Arjan Bredenoord, UMC Amsterdam

Title: Determination of dose and injection pattern of EP-104GI through dose escalation in RESOLVE: a Phase 1b/2, multicenter trial to evaluate safety, tolerability, pharmacokinetics and efficacy in adults with EoE.
Presenter: Evan Dellon, University of North Carolina

Materials will be available after the presentations on Eupraxia's website at:

https://eupraxiapharma.com/our-science/clinical-trials-and-publications/default.aspx

Investor event at DDW 2026

The Company will also be hosting a virtual investor event on Monday, May 4 at 7am CT / 8am ET at Digestive Disease Week (DDW). The event will feature key opinion leaders (KOLs) Evan S. Dellon, MD, MPH (University of North Carolina School of Medicine) and Jeffrey D. Mosko, MD, MSc, FRCPC (University of Toronto), who will discuss the definition, prevalence, and treatment of recurrent esophageal strictures.

Company management will also highlight the potential of its lead product candidate EP-104GI for the prevention of esophageal strictures. EP-104GI is a long-acting submucosal corticosteroid formulation to be injected within esophageal tissues, which has the potential to increase patient adherence by requiring fewer interventions while addressing local inflammation.

Register for the event here - https://lifescievents.com/event/w0za2fn/

About Eupraxia Pharmaceuticals Inc.

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Diffusphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the Diffusphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods.

The precision of Eupraxia's Diffusphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas.

Eupraxia's EP-104GI is currently in a Phase 1b/2 trial, the RESOLVE trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company's website at: www.eupraxiapharma.com.

For investor and media inquiries, please contact:

James Meikle, Eupraxia Pharmaceuticals Inc.
236.330.7084
jmeikle@eupraxiapharma.com

or

Kevin Gardner, on behalf of:
Eupraxia Pharmaceuticals Inc.
617.283.2856
kgardner@lifesciadvisors.com

SOURCE Eupraxia Pharmaceuticals Inc.

Source: View Original Filing on SEC EDGAR

FAQ

What does Eupraxia Pharmaceuticals (EPRX) announce in this 6-K?

Eupraxia announces it will present four EP-104GI abstracts at Digestive Disease Week 2026 and host a virtual investor event. The filing also highlights its Diffusphere technology and prior Phase 2b success of EP-104IAR in knee osteoarthritis pain.

What data on EP-104GI will Eupraxia (EPRX) present at DDW 2026?

Eupraxia will share Phase 1b/2 RESOLVE trial data showing 36‑week improvements in histological features, endoscopic inflammation and fibrosis, dysphagia durability, and dose and injection pattern determination for EP-104GI in adults with eosinophilic esophagitis.

When and where is Eupraxia’s DDW 2026 oral presentation on EP-104GI?

The oral presentation, within the “EoE: Advances in Management” session, is scheduled for May 3, 2026, from 10:15 to 10:30 AM CDT in Chicago, Illinois, focusing on escalating EP-104GI doses and 36‑week histological improvements in eosinophilic esophagitis.

What is Eupraxia’s virtual investor event at DDW 2026 about?

The virtual investor event on May 4 at 7am CT / 8am ET will feature key opinion leaders discussing recurrent esophageal strictures and allow company management to highlight EP-104GI’s potential to prevent strictures using long-acting, locally delivered corticosteroid therapy.

What is EP-104GI and how is it administered?

EP-104GI is a long-acting submucosal corticosteroid formulation designed for injection into esophageal tissues. It aims to deliver localized, extended-release therapy to treat eosinophilic esophagitis and potentially prevent esophageal strictures while requiring fewer interventions for patients.

What other programs does Eupraxia Pharmaceuticals (EPRX) highlight?

Eupraxia notes EP-104IAR, which in the Phase 2b SPRINGBOARD trial for knee osteoarthritis pain met its primary endpoint and three of four secondary endpoints. The company is also developing additional long-acting formulations for inflammatory joint diseases and oncology indications.

What is Eupraxia’s Diffusphere technology platform?

Diffusphere is a proprietary polymer-based microsphere delivery technology designed for hyper-local, extended-release dosing of existing and novel drugs. It aims to improve safety, tolerability, efficacy and duration by maintaining stable drug levels in targeted tissues and reducing systemic exposure peaks and troughs.

Filing Exhibits & Attachments

1 document

Press Releases